A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

PHASE2CompletedINTERVENTIONAL

Enrollment

164

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

July 13, 2016

Study Completion Date

July 27, 2016

Conditions

Schizophrenia

Interventions

DRUG

TAK-063 20 mg

TAK-063 tablet.

DRUG

Placebo

TAK-063 matching-placebo tablet.

Trial Locations (15)

Springdale

Culver City

Lemon Grove

Long Beach

Pico Rivera

Lauderhill

Orlando

Atlanta

Lake Charles

St Louis

Las Vegas

Oklahoma City

Austin

Dallas

Houston